Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) EBITDA Margin (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed EBITDA Margin for 5 consecutive years, with 15124.81% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EBITDA Margin rose 1900177.0% year-over-year to 15124.81%, compared with a TTM value of 214719.78% through Jun 2025, up 21531577.0%, and an annual FY2024 reading of 2591.26%, down 219577.0% over the prior year.
  • EBITDA Margin was 15124.81% for Q2 2025 at SAB Biotherapeutics, up from 8726.26% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 15124.81% in Q2 2025 and bottomed at 8726.26% in Q4 2024.
  • Average EBITDA Margin over 5 years is 340.83%, with a median of 166.12% recorded in 2021.
  • The sharpest move saw EBITDA Margin crashed -1211840bps in 2024, then surged 1900177bps in 2025.
  • Year by year, EBITDA Margin stood at 114.75% in 2021, then tumbled by -217bps to 363.74% in 2022, then soared by 1033bps to 3392.14% in 2023, then plummeted by -357bps to 8726.26% in 2024, then skyrocketed by 273bps to 15124.81% in 2025.
  • Business Quant data shows EBITDA Margin for SABS at 15124.81% in Q2 2025, 8726.26% in Q4 2024, and 3876.95% in Q2 2024.